No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
KYMR240517C35000
- 2.80
- -2.55-47.66%
15min DelayTrading May 15 10:13 ET
2.80High2.80Low
2.80Open5.35Pre Close1 Volume25 Open Interest35.00Strike Price280.00Turnover199.59%IV5.46%PremiumMay 17, 2024Expiry Date0.63Intrinsic Value100Multiplier2DDays to Expiry2.17Time Value100Contract SizeAmericanOptions Type0.5617Delta0.0677Gamma13.84Leverage Ratio-0.5249Theta0.0012Rho7.77Eff Leverage0.0115Vega
Intraday
- 5D
- 1D
News
Express News | Kymera Therapeutics Inc - KT-333 Phase 1 Study Ongoing With Additional Data Expected in Second Half of 2024
Kymera Therapeutics to Present New Clinical Data From the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date Updated data to be presented at the European Hematology Association (EHA) Annual
Analysts Offer Insights on Healthcare Companies: Valneva (VALN), Janux Therapeutics Inc (JANX) and Kymera Therapeutics (KYMR)
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using target
Earnings Call Summary | Kymera Therapeutics(KYMR.US) Q1 2024 Earnings Conference
The following is a summary of the Kymera Therapeutics, Inc. (KYMR) Q1 2024 Earnings Call Transcript:Financial Performance:Kymera reported Q1 2024 revenue of $10.3 million, solely from its collaboratio
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript
Comments
Despite lower revenue forecasts, analysts see no long-term impact on the business's intrinsic value. Opinions vary, with the most optimistic analyst valuing it at US$112 and the most pessimistic at US$26.00 per share. No changes were made to next year's loss forecasts, but revenue estimates were downgraded. The company's long-term earnings trajectory is deemed more crucial than next year's performance.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Analysts Are Pretty Bullish On The Stock After Recent ResultsKymera Therapeutics' high P/S ratio could imply investors' bullish stance outweighs analysts. However, without major growth improvement, the high P/S value may not sustain this positive sentiment, potentially making the stock overvalued.
$Kymera Therapeutics(KYMR.US$ Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment From Sanofi![]()
$Kymera Therapeutics(KYMR.US$ Director BVF PARTNERS L P/IL purchased 414.11K shares of Common Stocks on Nov 2, 3, 2023 at an average price of $12.8019 for a total value of $5.3 million.
This transaction involves other related parties: BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL and LAMPERT MARK N.
This transaction involves other related parties: BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL and LAMPERT MARK N.
$Kymera Therapeutics(KYMR.US$ Kymera Therapeutics: KT-413 (IRAKIMiD) Development to Be Discontinued for Strategic Reasons >KYMR
Dow Jones· 6 mins ago
Dow Jones· 6 mins ago
Read more